What's Behind ImmunoGen's Blowout Q4 Results
ImmunoGen (NASDAQ: IMGN) floundered throughout much of 2019, with the stock down more than 50% year to date by October. But some encouraging news from a late-stage clinical study evaluating mirvetuximab soravtansine renewed investors' enthusiasm soon afterward. ImmunoGen stock soared and kept the momentum going in subsequent months.
The biotech announced its 2019 fourth-quarter and full-year results before the market opened on Friday, fueling the fire even more. Here are the highlights from ImmunoGen's Q4 update.
Image source: Getty Images.
Source Fool.com
